目的 研究胺碘呋酮合并丹参酮ⅡA磺酸钠注射液用于急性心肌梗死后恶性心律失常的临床疗效及安全性。方法 筛选急性心肌梗死导致恶性心律失常的患者160例，随机分为治疗组（80例）和对照组（80例），对照组患者给予生理盐水稀释4 mg/kg的胺碘呋酮20 mL，iv后维持（1.25±0.25）mg/min，若症状缓解则酌情减少剂量；注射后若病情控制不佳，则可每隔20 min再追加（2±0.5）mg/kg的静脉负荷量1～2次。治疗组患者在对照组基础上加用丹参酮ⅡA磺酸钠注射液，使用前使用5%葡萄糖注射液375 mL溶解，静脉注射，100～200 mg/次，2次/日，10～15 d为一疗程，根据病情连续使用2～3个疗程，治疗结束后，分析两组治疗效果及不良反应。结果 治疗组有效总有效率为92.5%，对照组为76.25%，两组相比差异有统计学意义（P＜0.05），两组治疗后左心室射血分数和左心室短轴缩短率指标与治疗前相比差异有统计学意义（P＜0.05）。结论 胺碘呋酮联合丹参酮ⅡA磺酸钠注射液是一种治疗急性心肌梗死后诱发恶性心律失常较为有前景的联合用药。

Objective To evaluate the clinical efficiency and security of amiodaron combined with Sulfotanshinone Sodium Injection (SSI) in the treatment of malignant arrhythmia caused by acute myocardial infarction (AMI). Methods The patients (160 cases) diagnosed as AMI were randomly divided into treatment (80 cases) and control (80 cases) groups. The patients in the control group were iv administered with 20 mL amiodaron (4 mg/kg, diluted with physiological saline), then maintained the dose of (1.25 ± 0.25) mg/min. If the disease was controlled, the dosage could be reduced; if not, the dosage was increased to (2 ± 0.5) mg/kg every 20 min, once or twice. The patients in the treatment group were iv administered with SSI dissolved in 375 mL of 5% glucose, with the dose of 100—200 mg, twice daily, for 10—15 d as one course. Two groups were treated for 2—3 courses according to the disease symtom. After the treatment, the therapeutic effects and adverse reactions were observed. Results The efficiency of the patients in the treatment and control groups was 92.5% and 76.25% with the significant difference (P < 0.05). The indexes of LVEF and FS were significant difference before and after the treatments (P < 0.05). Conclusion Amiodaron combined with SSI is a relatively promising medicine for the treatment of malignant arrhythmia after AMI.